stockportfolio.pro
ICU Medical, Inc. (ICUI)
Healthcare · Medical Instruments & Supplies · NasdaqGS
ICU Medical, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $379.37M | $1.29B | $1.40B | $1.27B | $1.27B | $1.32B | $2.28B | $2.26B | $2.38B | $2.21B |
| Gross profit | $201.40M | $426.10M | $570.03M | $471.86M | $461.50M | $491.49M | $697.76M | $739.87M | $824.78M | $822.04M |
| Net income | $63.08M | $68.64M | $28.79M | $101.03M | $86.87M | $103.14M | $-74.29M | $-29.66M | $-117.69M | $732,000 |
| Net margin | 16.6% | 5.3% | 2.1% | 8.0% | 6.8% | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% |
Source: ICU Medical, Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into ICUI stock?
At today's market cap of $3.52B, ICU Medical, Inc. is priced for free-cash-flow growth of about 16.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $91.80M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -6.8%/yr over the last five fiscal years and revenue 11.7%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of ICU Medical, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ICUI in your portfolio →
ICU Medical, Inc. financial history by metric
About ICU Medical, Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
ICU Medical, Inc. — frequently asked questions
What is ICU Medical, Inc.'s revenue?
ICU Medical, Inc. (ICUI) reported revenue of $2.21B for fiscal year 2025, down 7.1% from the prior year, according to its SEC filings.
Is ICU Medical, Inc. profitable?
Yes. ICUI earned net income of $732,000 in fiscal 2025, a net margin of 0.0%.
What is ICUI's P/E ratio?
ICU Medical, Inc. trades at a price-to-earnings ratio of about 75.8 based on the latest data in our nightly-refreshed cache.
How fast is ICU Medical, Inc. growing?
ICUI's revenue grew at roughly 11.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does ICU Medical, Inc. have?
As of fiscal year 2025, ICUI carried roughly $1.28B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is ICU Medical, Inc.'s gross margin?
ICUI's gross margin was 37.2% in fiscal 2025 — gross profit of $822.04M on revenue of $2.21B.
What is ICU Medical, Inc.'s market cap?
ICU Medical, Inc. (ICUI) has a market capitalization of about $3.52B, based on the latest data in our nightly-refreshed cache.
When does ICU Medical, Inc.'s fiscal year end?
ICUI's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ICUI stock?
At today's market cap of $3.52B, ICU Medical, Inc. is priced for free-cash-flow growth of about 16.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $91.80M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -6.8%/yr over the last five fiscal years and revenue 11.7%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from ICU Medical, Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.